vs
Orthofix Medical Inc.（OFIX）与Xometry, Inc.（XMTR）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Xometry, Inc.的1.1倍（$219.9M vs $192.4M），Orthofix Medical Inc.净利率更高（-1.0% vs -4.5%，领先3.5%），Xometry, Inc.同比增速更快（29.5% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-5.9M），过去两年Xometry, Inc.的营收复合增速更高（25.2% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Xometry是一家按需制造零部件采购线上平台，服务覆盖原型研发到规模化生产的全流程需求，为各行业客户高效匹配制造产能，简化定制零部件的采购流程，助力企业缩短产品落地周期。
OFIX vs XMTR — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$192.4M
营收增速更快
XMTR
高出27.5%
2.0%
净利率更高
OFIX
高出3.5%
-4.5%
自由现金流更多
OFIX
多$22.7M
$-5.9M
两年增速更快
XMTR
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $192.4M |
| 净利润 | $-2.2M | $-8.6M |
| 毛利率 | 71.1% | 39.1% |
| 营业利润率 | 0.2% | -4.6% |
| 净利率 | -1.0% | -4.5% |
| 营收同比 | 2.0% | 29.5% |
| 净利润同比 | 92.4% | 12.7% |
| 每股收益（稀释后） | $-0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXXMTR
| Q4 25 | $219.9M | $192.4M | ||
| Q3 25 | $205.6M | $180.7M | ||
| Q2 25 | $203.1M | $162.5M | ||
| Q1 25 | $193.6M | $151.0M | ||
| Q4 24 | $215.7M | $148.5M | ||
| Q3 24 | $196.6M | $141.7M | ||
| Q2 24 | $198.6M | $132.6M | ||
| Q1 24 | $188.6M | $122.7M |
净利润OFIXXMTR
| Q4 25 | $-2.2M | $-8.6M | ||
| Q3 25 | $-22.8M | $-11.6M | ||
| Q2 25 | $-14.1M | $-26.4M | ||
| Q1 25 | $-53.1M | $-15.1M | ||
| Q4 24 | $-29.1M | $-9.9M | ||
| Q3 24 | $-27.4M | $-10.2M | ||
| Q2 24 | $-33.4M | $-13.7M | ||
| Q1 24 | $-36.0M | $-16.6M |
毛利率OFIXXMTR
| Q4 25 | 71.1% | 39.1% | ||
| Q3 25 | 72.2% | 39.9% | ||
| Q2 25 | 68.7% | 40.1% | ||
| Q1 25 | 62.8% | 37.3% | ||
| Q4 24 | 69.0% | 39.7% | ||
| Q3 24 | 68.7% | 39.4% | ||
| Q2 24 | 67.8% | 39.9% | ||
| Q1 24 | 67.5% | 39.0% |
营业利润率OFIXXMTR
| Q4 25 | 0.2% | -4.6% | ||
| Q3 25 | -8.3% | -6.1% | ||
| Q2 25 | -7.9% | -6.3% | ||
| Q1 25 | -25.2% | -10.2% | ||
| Q4 24 | -5.3% | -7.8% | ||
| Q3 24 | -9.6% | -8.1% | ||
| Q2 24 | -12.5% | -11.5% | ||
| Q1 24 | -15.6% | -14.6% |
净利率OFIXXMTR
| Q4 25 | -1.0% | -4.5% | ||
| Q3 25 | -11.1% | -6.4% | ||
| Q2 25 | -6.9% | -16.3% | ||
| Q1 25 | -27.4% | -10.0% | ||
| Q4 24 | -13.5% | -6.7% | ||
| Q3 24 | -13.9% | -7.2% | ||
| Q2 24 | -16.8% | -10.3% | ||
| Q1 24 | -19.1% | -13.5% |
每股收益（稀释后）OFIXXMTR
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.36 | — | ||
| Q1 25 | $-1.35 | — | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.71 | — | ||
| Q2 24 | $-0.88 | — | ||
| Q1 24 | $-0.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $219.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $275.6M |
| 总资产 | $850.6M | $703.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXXMTR
| Q4 25 | $82.0M | $219.1M | ||
| Q3 25 | $62.9M | $224.5M | ||
| Q2 25 | $65.6M | $225.8M | ||
| Q1 25 | $58.0M | $231.4M | ||
| Q4 24 | $83.2M | $239.8M | ||
| Q3 24 | $30.1M | $234.0M | ||
| Q2 24 | $26.4M | $240.9M | ||
| Q1 24 | $27.0M | $253.8M |
总债务OFIXXMTR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXXMTR
| Q4 25 | $450.0M | $275.6M | ||
| Q3 25 | $442.5M | $272.0M | ||
| Q2 25 | $458.3M | $270.4M | ||
| Q1 25 | $458.3M | $309.9M | ||
| Q4 24 | $503.1M | $314.5M | ||
| Q3 24 | $525.9M | $315.2M | ||
| Q2 24 | $546.0M | $315.8M | ||
| Q1 24 | $570.3M | $320.4M |
总资产OFIXXMTR
| Q4 25 | $850.6M | $703.7M | ||
| Q3 25 | $832.6M | $698.9M | ||
| Q2 25 | $837.2M | $687.0M | ||
| Q1 25 | $823.1M | $690.1M | ||
| Q4 24 | $893.3M | $680.1M | ||
| Q3 24 | $867.9M | $678.2M | ||
| Q2 24 | $882.0M | $678.6M | ||
| Q1 24 | $906.0M | $692.5M |
负债/权益比OFIXXMTR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $4.4M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-5.9M |
| 自由现金流率自由现金流/营收 | 7.6% | -3.0% |
| 资本支出强度资本支出/营收 | 4.9% | 5.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-24.1M |
8季度趋势，按日历期对齐
经营现金流OFIXXMTR
| Q4 25 | $27.7M | $4.4M | ||
| Q3 25 | $12.4M | $5.8M | ||
| Q2 25 | $11.6M | $-427.0K | ||
| Q1 25 | $-18.4M | $-3.7M | ||
| Q4 24 | $23.7M | $9.1M | ||
| Q3 24 | $11.7M | $-3.6M | ||
| Q2 24 | $9.0M | $-9.1M | ||
| Q1 24 | $-18.6M | $-11.7M |
自由现金流OFIXXMTR
| Q4 25 | $16.8M | $-5.9M | ||
| Q3 25 | $2.5M | $-1.7M | ||
| Q2 25 | $4.5M | $-7.4M | ||
| Q1 25 | $-25.1M | $-9.2M | ||
| Q4 24 | $15.2M | $4.5M | ||
| Q3 24 | $6.3M | $-8.4M | ||
| Q2 24 | $-360.0K | $-13.5M | ||
| Q1 24 | $-29.1M | $-16.1M |
自由现金流率OFIXXMTR
| Q4 25 | 7.6% | -3.0% | ||
| Q3 25 | 1.2% | -0.9% | ||
| Q2 25 | 2.2% | -4.5% | ||
| Q1 25 | -13.0% | -6.1% | ||
| Q4 24 | 7.0% | 3.1% | ||
| Q3 24 | 3.2% | -6.0% | ||
| Q2 24 | -0.2% | -10.2% | ||
| Q1 24 | -15.4% | -13.1% |
资本支出强度OFIXXMTR
| Q4 25 | 4.9% | 5.3% | ||
| Q3 25 | 4.8% | 4.1% | ||
| Q2 25 | 3.5% | 4.3% | ||
| Q1 25 | 3.5% | 3.6% | ||
| Q4 24 | 4.0% | 3.1% | ||
| Q3 24 | 2.7% | 3.4% | ||
| Q2 24 | 4.7% | 3.3% | ||
| Q1 24 | 5.6% | 3.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
